We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Effect of Biologic and Targeted Synthetic Drugs on Work- and Productivity-related Outcomes for Patients with Psoriatic Arthritis: A Systematic Review.
- Authors
Iragorri, Nicolas; Hofmeister, Mark; Spackman, Eldon; Hazlewood, Glen S.
- Abstract
<bold>Objective: </bold>To systematically review the effects of biologic therapies for psoriatic arthritis [secukinumab, ustekinumab, adalimumab, etanercept, certolizumab pegol (CZP), apremilast, golimumab (GOL), or infliximab (IFX)] on work productivity.<bold>Methods: </bold>A systematic review of Medline, EMBASE, CENTRAL, and ClinicalTrials.gov was conducted to identify randomized controlled trials reporting on work productivity outcomes at the end of the placebo-controlled double-blind period.<bold>Results: </bold>There were 7959 records identified. Full text of 377 records was further assessed for eligibility, of which 5 trials were included. All included trials were assessed with the Cochrane Risk of Bias Tool, and 4 out of 5 were judged to be of low risk of bias in most domains. Improvements in self-assessed work productivity were observed in 5 trials (IFX, GOL, CZP, ustekinumab, and apremilast), ranging from a mean difference of -0.9 to -1.8 on a 1-10 scale of self-assessed work productivity (negative change represents improvement), although statistical significance of the results was not reported for CZP and apremilast. Treatment with CZP resulted in a statistically significant reduction in absenteeism (200 mg) and presenteeism (200 and 400 mg). IFX and GOL reported a nonsignificant reduction of absenteeism. The Work Productivity Survey, the Work Limitations Questionnaire, and visual analog scales were used to measure work productivity.<bold>Conclusion: </bold>Treatment with IFX, GOL, CZP, ustekinumab, and apremilast resulted in improvements in self-reported work productivity. A pooled analysis was not possible because of the clinical heterogeneity of the trials and variability in outcome reporting.
- Subjects
BIOTHERAPY; ANTIRHEUMATIC agents; EMPLOYMENT; IMMUNOSUPPRESSIVE agents; LABOR productivity; PSORIATIC arthritis; SYSTEMATIC reviews; TREATMENT effectiveness
- Publication
Journal of Rheumatology, 2018, Vol 45, Issue 8, p1124
- ISSN
0315-162X
- Publication type
journal article
- DOI
10.3899/jrheum.170874